Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kebing Yu

Showing results (41-50 of 48) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 48 results.
Cell Chemical Biology|May 16, 2025
Engineering ERα degraders with pleiotropic ubiquitin ligase ligands maximizes therapeutic efficacy by co-opting distinct effector ligasesAnna Shemorry, Willem den Besten, Melinda M Mulvihill, et al.
Biorxiv : the Preprint Server for Biology|May 10, 2023
An RNA Damage Response Network Mediates the Lethality of 5-FU in Clinically Relevant Tumor TypesJung-Kuei Chen, Karl A Merrick, Yi Wen Kong, et al.
Cell Reports. Medicine|October 8, 2024
An RNA damage response network mediates the lethality of 5-FU in colorectal cancerJung-Kuei Chen, Karl A Merrick, Yi Wen Kong, et al.
Analytical Chemistry|March 6, 2023
Quantifying KRAS G12C Covalent Drug Inhibitor Activity in Mouse Tumors Using Mass SpectrometryJohn C Tran, Thomas Hunsaker, Christina Bell, et al.
Nature|December 10, 2015
Phosphorylation and linear ubiquitin direct A20 inhibition of inflammationIngrid E Wertz, Kim Newton, Dhaya Seshasayee, et al.
Nature|January 14, 2016
Erratum: Phosphorylation and linear ubiquitin direct A20 inhibition of inflammationIngrid E Wertz, Kim Newton, Dhaya Seshasayee, et al.
Nature|October 19, 2017
USP7 small-molecule inhibitors interfere with ubiquitin bindingLorna Kategaya, Paola Di Lello, Lionel Rougé, et al.
Journal of Medicinal Chemistry|March 2, 2026
Discovery and Characterization of Divarasib (GDC-6036), a Potent Covalent Inhibitor of KRAS G12CNicholas F Endres, Steven Do, Rana Mroue, et al.
Pageof 5

Showing results (41-50 of 48) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 48 results.
Cell Chemical Biology|May 16, 2025
Engineering ERα degraders with pleiotropic ubiquitin ligase ligands maximizes therapeutic efficacy by co-opting distinct effector ligasesAnna Shemorry, Willem den Besten, Melinda M Mulvihill, et al.
Biorxiv : the Preprint Server for Biology|May 10, 2023
An RNA Damage Response Network Mediates the Lethality of 5-FU in Clinically Relevant Tumor TypesJung-Kuei Chen, Karl A Merrick, Yi Wen Kong, et al.
Cell Reports. Medicine|October 8, 2024
An RNA damage response network mediates the lethality of 5-FU in colorectal cancerJung-Kuei Chen, Karl A Merrick, Yi Wen Kong, et al.
Analytical Chemistry|March 6, 2023
Quantifying KRAS G12C Covalent Drug Inhibitor Activity in Mouse Tumors Using Mass SpectrometryJohn C Tran, Thomas Hunsaker, Christina Bell, et al.
Nature|December 10, 2015
Phosphorylation and linear ubiquitin direct A20 inhibition of inflammationIngrid E Wertz, Kim Newton, Dhaya Seshasayee, et al.
Nature|January 14, 2016
Erratum: Phosphorylation and linear ubiquitin direct A20 inhibition of inflammationIngrid E Wertz, Kim Newton, Dhaya Seshasayee, et al.
Nature|October 19, 2017
USP7 small-molecule inhibitors interfere with ubiquitin bindingLorna Kategaya, Paola Di Lello, Lionel Rougé, et al.
Journal of Medicinal Chemistry|March 2, 2026
Discovery and Characterization of Divarasib (GDC-6036), a Potent Covalent Inhibitor of KRAS G12CNicholas F Endres, Steven Do, Rana Mroue, et al.
Pageof 5